| Literature DB >> 34660827 |
Jinlong Zhao1,2, Minghui Luo2,3, Guihong Liang2,3, Ming Wu1,2, Jianke Pan2,3, Ling-Feng Zeng2,3, Weiyi Yang2,3, Jun Liu2,3,4.
Abstract
BACKGROUND: The pathogenesis of rotator cuff tears remains unclear, and there is a lack of high-quality evidence-based research on the risk factors for supraspinatus tears.Entities:
Keywords: meta-analysis; risk factors; rotator cuff; supraspinatus tears
Year: 2021 PMID: 34660827 PMCID: PMC8516389 DOI: 10.1177/23259671211042826
Source DB: PubMed Journal: Orthop J Sports Med ISSN: 2325-9671
Search Strategy
| PubMed (up to January 2021): 502 results |
| ((Risk Factors[MeSH Terms]) OR (risk factor)) AND ((((((Rotator Cuff Injury[Title/Abstract]) OR (supraspinatus tears[Title/Abstract]) OR (Rotator Cuff Tears[Title/Abstract])) OR (Rotator Cuff Tear[Title/Abstract])) OR (Rotator Cuff Tears[MeSH Terms])) OR (Rotator Cuff Tendinosis[Title/Abstract])) OR (Rotator Cuff Tendinitis[Title/Abstract])) |
| Embase (up to January 2021): 266 results |
| 1. ‘risk factors’/exp OR ‘risk factors’: ab, ti |
| Web of Science: 219 results |
| 1. AB = (risk factors OR risk factor) |
Figure 1.PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart.
Characteristics of the Included Studies
| Lead Author (Year) | Country | Study Design (LOE) | No. of Patients | Imaging Modality | NOS or AHRQ Score | |
|---|---|---|---|---|---|---|
| ST | Non-ST | |||||
| Watanabe (2018)
| Japan | Cohort (2) | 54 | 54 | MRI | 6 |
| Applegate (2017)
| USA | Cohort (2) | 156 | 1070 | NR | 7 |
| Atala (2021)
| Argentina | Cohort (2) | 52 | 53 | MRI | 8 |
| Blonna (2016)
| Italy | Cohort (2) | 40 | 80 | MRI | 8 |
| Cunningham (2018)
| Switzerland | Cohort (2) | 33 | 38 | MRI | 7 |
| Figueiredo (2019)
| Brazil | Cohort (2) | 211 | 567 | MRI | 6 |
| Haveri (2020)
| India | Cross-sectional (3) | 69 | 31 | MRI | 8 |
| Jeong (2017)
| Korea | Cross-sectional (3) | 23 | 355 | US | 6 |
| Mehta (2020)
| USA | Cohort (2) | 49 | 305 | US | 9 |
All included studies received ethics approval. AHRQ, Agency for Healthcare Research and Quality; LOE, level of evidence; MRI, magnetic resonance imaging; NOS, Newcastle-Ottawa Scale; NR, not reported; ST, supraspinatus tear; US, ultrasound.
Figure 2.Meta-analysis forest plot for age. IV, inverse variance methods.
Figure 3.Meta-analysis forest plot for body mass index. IV, inverse variance methods.
Figure 4.Meta-analysis forest plot of male sex. M-H, Mantel-Haenszel.
Figure 5.Meta-analysis forest plot of female sex. M-H, Mantel-Haenszel.
Figure 6.Meta-analysis forest plot of dominant arm. M-H, Mantel-Haenszel.
Figure 7.Meta-analysis forest plot of smoking. M-H, Mantel-Haenszel.
Figure 8.Meta-analysis forest plot of diabetes mellitus. M-H, Mantel-Haenszel.
Figure 9.Meta-analysis forest plot of hypertension. M-H, Mantel-Haenszel.
Figure 10.Meta-analysis forest plot of thyroid disease. M-H, Mantel-Haenszel.
Figure 11.Meta-analysis forest plot of the critical shoulder angle. IV, inverse variance methods.
Assessment of Publication Bias
| Analyzed Factor | No. of Studies | Begg Test | |
|---|---|---|---|
|
|
| ||
| Age | 8 | 2.60 | .09 |
| Body mass index | 4 | –0.34 | ≥.999 |
| Male sex | 9 | 1.15 | .251 |
| Female sex | 8 | 0.62 | .536 |
| Arm dominance | 4 | –0.34 | ≥.999 |
| Smoking | 6 | 0.38 | .707 |
| Diabetes mellitus | 3 | 0.0000 | ≥.999 |
| Hypertension | 2 | 0.0000 | ≥.999 |
| Thyroid disease | 2 | 0.0000 | ≥.999 |
| Critical shoulder angle | 2 | 0.0000 | ≥.999 |
Newcastle-Ottawa Scale (NOS) for Risk of Bias Assessment of the Cohort Studies Included in the Review
| Lead Author (Year) | Selection Items | Comparability | Outcome Items | NOS Score | |||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |||
| Watanabe (2018)
| ☆ | ★ | ★ | ★ | ★ | ★ | ☆ | ★ | 6 |
| Applegate (2017)
| ☆ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 7 |
| Atala (2021)
| ☆ | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 8 |
| Blonna (2016)
| ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 8 |
| Cunningham (2018)
| ☆ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 7 |
| Figueiredo (2019)
| ★ | ★ | ★ | ☆ | ★ | ☆ | ★ | ★ | 6 |
| Mehta (2020)
| ★ | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 9 |
★, 1 point; ★★, 2 points; ☆, 0 points.
Key to items: 1 = representativeness of exposed cohort; 2 = selection of nonexposed; 3 = ascertainment of exposure; 4 = outcome not present at start; 5 = assessment of outcome; 6 = adequate follow-up length; 7 = adequacy of follow-up.
AHRQ Score Assessing the Quality of the Cross-Sectional Studies Included in the Review
| Item | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lead Author (Year) | 1 | 2 | 3 | 4 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | AHRQ Score |
| Haveri (2020)
| + | + | + | + | NA | + | + | NA | + | + | – | 8 |
| Jeong (2017)
| + | + | + | NA | NA | + | + | NA | – | + | NA | 6 |
AHRQ, Agency for Healthcare Research and Quality; NA, unclear; +, yes; –, no.
Key to items: 1 = define the source of information (survey, record review); 2 = list inclusion and exclusion criteria for exposed and unexposed patients (cases and controls) or refer to previous publications; 3 = indicate time period used for identifying patients; 4 = indicate whether or not patients were consecutive if not population-based; 5 = indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants; 6 = describe any assessments undertaken for quality assurance purposes (eg, test/retest of primary outcome measurements); 7 = explain any patient exclusions from analysis; 8 = describe how confounding was assessed and/or controlled; 9 = if applicable, explain how missing data were handled in the analysis; 10 = summarize patient response rates and completeness of data collection; 11 = clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained.